Trendlines Establishes China-Based China-Israel New Trend with Shoushan Wealth Holdings

Shoushan and Trendlines Joint Venture Signing

Shoushan’s Chairman, Wu Liangjun (at left) with Todd Dollinger, Chairman and CEO of Trendlines, sealing the Joint Venture

Editor’s note: News of the joint venture appeared in The Business Times.

The Joint Venture will assist Trendlines’ and other Israeli and Singaporean medical device companies with commercialization, manufacturing and other activities in China. Parties to raise venture funds to invest in medical companies.

The Trendlines Group Ltd. and Shoushan Wealth Holdings, a Chinese private equity investment, investment banking, funds management and financial services company, jointly announced the signing of the Definitive Agreement to establish and manage China-Israel New Trend (Taizhou) Medical Technology Co. Ltd., a Shanghai-based Joint Venture to help Trendlines’ medical sector portfolio companies and other Israeli, Singaporean and other medical companies penetrate the Chinese market. The Joint Venture will be held 51% by Trendlines and 49% by Shoushan.

The Joint Venture, for which execution of the term sheet was announced on 16 December 2016, is headquartered in Shanghai with additional staff in Israel. It will provide services to select Israeli, Singaporean and other medical device companies, including support in establishing manufacturing capabilities in China, obtaining regulatory approval for sale of products in China, and managing strategic partner relationships. The core of the JV’s business model is to facilitate the establishment of new manufacturing and commercialization partnerships for the Israeli, Singaporean and other medical device companies.

Trendlines and Shoushan intend to raise US dollar and Chinese RMB venture funds, which they will manage, to invest in Trendlines’ portfolio companies and other Israeli, Israel-related, Singaporean and other medical device companies. The parties intend to offer a combination of financial investment by the Funds and assistance in penetrating China through the Joint Venture.

Todd Dollinger, Trendlines’ Chairman and CEO, said: “Trendlines views the Chinese market  as critical to maximizing the success of our portfolio companies and the agreement with Shoushan is central to supporting and developing our companies in China. We have been working in China for some five years; our first Chinese employee, Eddy Wang, joined us as Director of our China Office three years ago. We have been patient in building our China-based business; in Shoushan – with which we have spent more than a year developing our relationship and modus operandi – we have found a partner with which we share common values. Our work with Shoushan is part of Trendlines’ dedication to and active involvement in our portfolio companies.”

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize